Trial Profile
A study evaluating effect of high dose therapy of Plerixafor with autologous stem cell support in poor mobilizing lymphoma patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2017
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Autologous stem cell therapy; Granulocyte colony-stimulating factors
- Indications Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 19 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology